Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.
Authors
- W. WANG
- Leonardo A. Meza‐Zepeda (ORCID: https://orcid.org/0000-0003-3056-212X)
- José L. Mondaza-Hernández (ORCID: https://orcid.org/0000-0002-5642-3796)
- Emily Z. Keung (ORCID: https://orcid.org/0000-0002-8783-8484)
- Melissa Amber Burgess (ORCID: https://orcid.org/0000-0002-5753-1422)
- D. Ingram
- Khalida M. Wani
- Hussein Tawbi
- Ola Myklebost
- Nadia Hindi
- Alexander Lazar
- Jesus Lopez-Marti
- David S. Moura
Institutions
- Oslo University Hospital (NO)
- The University of Texas MD Anderson Cancer Center (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- University of Pittsburgh Medical Center (US)
- Comunidad de Madrid (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2580
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00